Keros Therapeutics (NASDAQ:KROS) Lowered to “Strong Sell” Rating by Zacks Research

Zacks Research cut shares of Keros Therapeutics (NASDAQ:KROS) from a hold rating to a strong sell rating in a report issued on Wednesday morning,Zacks.com reports.

A number of other brokerages also recently issued reports on KROS. Wall Street Zen downgraded shares of Keros Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Saturday, May 16th. Weiss Ratings cut shares of Keros Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a research report on Friday, May 15th. Three equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat, Keros Therapeutics has a consensus rating of “Hold” and an average target price of $20.40.

Keros Therapeutics Stock Performance

Shares of NASDAQ KROS opened at $10.22 on Wednesday. The firm has a 50 day moving average price of $10.73 and a two-hundred day moving average price of $12.72. The stock has a market cap of $202.27 million, a P/E ratio of -3.40 and a beta of 0.97. Keros Therapeutics has a 52-week low of $9.69 and a 52-week high of $22.55.

Keros Therapeutics (NASDAQ:KROS) last posted its quarterly earnings data on Thursday, May 14th. The company reported ($1.21) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.02) by ($0.19). Keros Therapeutics had a negative net margin of 256.60% and a negative return on equity of 17.04%. The company had revenue of $0.37 million during the quarter, compared to analyst estimates of $1.93 million. Analysts predict that Keros Therapeutics will post -5.19 earnings per share for the current fiscal year.

Insider Activity

In other news, Director Alpna Seth sold 2,625 shares of the stock in a transaction dated Thursday, June 4th. The shares were sold at an average price of $10.72, for a total transaction of $28,140.00. Following the transaction, the director owned 9,767 shares of the company’s stock, valued at $104,702.24. This represents a 21.18% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Julius Knowles sold 2,625 shares of the business’s stock in a transaction dated Thursday, June 4th. The shares were sold at an average price of $10.73, for a total value of $28,166.25. Following the completion of the sale, the director directly owned 10,958 shares of the company’s stock, valued at $117,579.34. The trade was a 19.33% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 8,425 shares of company stock worth $89,994. Company insiders own 12.60% of the company’s stock.

Institutional Trading of Keros Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the business. AQR Capital Management LLC acquired a new position in Keros Therapeutics during the 1st quarter valued at about $226,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of Keros Therapeutics by 15.5% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 22,166 shares of the company’s stock valued at $227,000 after purchasing an additional 2,982 shares in the last quarter. Goldman Sachs Group Inc. boosted its position in shares of Keros Therapeutics by 38.3% during the first quarter. Goldman Sachs Group Inc. now owns 740,606 shares of the company’s stock valued at $7,547,000 after buying an additional 205,022 shares during the last quarter. Creative Planning grew its holdings in Keros Therapeutics by 40.2% during the second quarter. Creative Planning now owns 24,226 shares of the company’s stock worth $323,000 after buying an additional 6,948 shares in the last quarter. Finally, Rhumbline Advisers raised its position in Keros Therapeutics by 16.0% in the 2nd quarter. Rhumbline Advisers now owns 51,815 shares of the company’s stock valued at $692,000 after buying an additional 7,146 shares during the last quarter. Institutional investors own 71.56% of the company’s stock.

About Keros Therapeutics

Keros Therapeutics, Inc (NASDAQ: KROS) is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapies for disorders of erythropoiesis and iron regulation. The company’s research centers on modulating the transforming growth factor-beta (TGF-β) superfamily to rebalance hematopoiesis and improve red blood cell production. By targeting key signaling pathways involved in anemia, Keros aims to provide new treatment options for patients with myelodysplastic syndromes, beta-thalassemia and other chronic anemias with significant unmet need.

The company’s lead product candidate, KER-050, is an engineered activin receptor ligand trap designed to restore effective erythropoiesis and reduce transfusion dependence in patients with anemia associated with myelodysplastic syndromes and primary myelofibrosis.